SD Biosensor Inc (137310) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SD Biosensor Inc (137310) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.90 Billion ≈ $10.09 Million USD) by net assets (₩3.07 Trillion ≈ $2.08 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SD Biosensor Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of SD Biosensor Inc for a breakdown of total debt and financial obligations.
SD Biosensor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SD Biosensor Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Sunway Petrochemical Engineering Co Ltd
SHE:002469
|
0.036x |
|
Sundiro Holding Co Ltd
SHE:000571
|
-0.031x |
|
WenYi Trinity Technology Co Ltd
SHG:600520
|
0.039x |
|
GurSel Turizm Tasimacilik Ve Servis Ticaret AS
IS:GRSEL
|
0.159x |
|
Alltop Technology Co Ltd
TWO:3526
|
0.099x |
|
Hosken Consolidated Investments Ltd
JSE:HCI
|
0.040x |
|
Aeolus Tyre Co Ltd
SHG:600469
|
0.052x |
|
Cikarang Listrindo Tbk PT
JK:POWR
|
0.074x |
Annual Cash Flow Conversion Efficiency for SD Biosensor Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of SD Biosensor Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SD Biosensor Inc (137310) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩2.93 Trillion ≈ $1.99 Billion |
₩156.53 Billion ≈ $106.08 Million |
0.053x | +162.38% |
| 2023-12-31 | ₩2.83 Trillion ≈ $1.92 Billion |
₩-242.32 Billion ≈ $-164.22 Million |
-0.086x | -128.33% |
| 2022-12-31 | ₩2.95 Trillion ≈ $2.00 Billion |
₩890.23 Billion ≈ $603.30 Million |
0.302x | -46.10% |
| 2021-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩1.23 Trillion ≈ $836.90 Million |
0.560x | -14.29% |
| 2020-12-31 | ₩757.55 Billion ≈ $513.38 Million |
₩495.38 Billion ≈ $335.71 Million |
0.654x | +5650.64% |
| 2019-12-31 | ₩137.91 Billion ≈ $93.46 Million |
₩-1.62 Billion ≈ $-1.10 Million |
-0.012x | -- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more